Weight Regain After Stopping GLP-1 Medication

Weight regain after stopping Mounjaro, Wegovy or other GLP-1 medicines is common. In the STEP 1 extension, people regained about two-thirds of the weight they had lost within a year of stopping semaglutide, and in SURMOUNT-4 people switched from tirzepatide to placebo regained about 14% of their body weight over a year. This reflects biology rather than a lack of willpower: these medicines treat appetite signals while you take them. Regain isn't inevitable for everyone, and planning with a prescriber, including maintenance options, can help. This guide explains the evidence and what to consider before stopping.

Why weight comes back

GLP-1 medicines mimic or enhance gut hormones that reduce appetite, increase fullness and slow stomach emptying. Mounjaro (tirzepatide) also acts on GIP receptors. While you take them, they help counteract the body's natural tendency to resist weight loss. When you stop:

• The medicine leaves your body. Weekly injections are cleared over several weeks, after which their effect on appetite fades.
• Appetite returns. Many people notice hunger and "food noise" increase within weeks of their last dose.
• The body's defences remain. After weight loss, the body adapts by lowering energy use and increasing hunger signals. These adaptations can persist long after weight loss.
• Habits are tested. Eating patterns that felt easy with medicine can become much harder without it.

This is why obesity is increasingly described as a chronic, relapsing condition, similar to high blood pressure, where treatment helps while it continues. Our guide to obesity as a chronic disease explains this in more depth.

What the trials show

Three trials give the clearest picture of what happens when GLP-1 medicines are stopped.

The STEP 1 extension

STEP 1 was the main trial of semaglutide 2.4 mg for weight management, published in the New England Journal of Medicine in 2021. After 68 weeks, a subgroup was followed for another year after stopping both the medicine and the trial's lifestyle programme. One year after stopping, participants on average had regained about two-thirds of the weight they had lost. Improvements in blood pressure, cholesterol, blood glucose (HbA1c) and other measures also moved back towards their starting values.

Importantly, on average, people still weighed less than when they started. But the benefit was much smaller than while on treatment.

STEP 4

STEP 4 asked a cleaner question: after people had lost weight on semaglutide, what happened if they continued versus switched to an identical-looking placebo injection? Those who continued lost more weight. Those who switched regained steadily over the 48 weeks.

SURMOUNT-4

SURMOUNT-4 did the same for tirzepatide. After 36 weeks on treatment, during which participants lost about 21% of their weight on average, they were randomised to continue or switch to placebo. Over the next year, the continuation group lost a further 5.5% on average, while the placebo group regained about 14% of their body weight. At the end of the trial (88 weeks), the continuation group was about 25% below starting weight and the placebo group about 10% below. Most people who continued maintained the large majority of their weight loss, while only a small minority of those on placebo did.

Do the health benefits reverse too?

Many of the health benefits of weight loss depend on keeping the weight off. In the STEP 1 extension, cardiometabolic improvements largely reversed in line with weight regain. This matters if you started treatment to improve blood pressure, blood glucose, joint pain, sleep apnoea or other weight-related conditions.

The cardiovascular benefits seen in the SELECT trial of semaglutide were observed in people who continued treatment. There is no evidence that these benefits persist after stopping. Our guide to long-term GLP-1 use discusses the long-term evidence.

Why people stop

People stop GLP-1 medicines for many reasons, and each has different implications:

• Reaching a goal weight and wanting to see whether they can maintain it without medicine
• Cost, particularly after the September 2025 rise in the UK list price of Mounjaro
• Side effects that don't settle
• Pregnancy or planning a pregnancy, when these medicines must be stopped in advance, as advised in the SmPCs
• NHS time limits, such as the two-year maximum for semaglutide under NICE TA875
• Supply problems or not responding to treatment
• Surgery or other medical reasons

If cost is the main reason, it may be worth discussing other options with your prescriber first, such as a lower maintenance dose or a different medicine. See our guide to the long-term cost of GLP-1 treatment and compare options on our prices page.

Planning to stop: what to discuss with your prescriber

Stopping should be a planned decision with your prescriber, not something done abruptly without support (unless there is a medical reason to stop immediately, such as pregnancy or a serious side effect).

Questions to ask

• Is now a sensible time to stop, given my health and progress?
• Should I reduce my dose gradually or stop at my current dose?
• Is there a lower-dose or alternative maintenance option?
• How often will you monitor my weight and health after stopping?
• What should prompt me to get back in touch?
• If I regain weight, could I restart, and how would that work?

Tapering

Some prescribers reduce the dose gradually before stopping, hoping to ease the return of appetite. This approach makes intuitive sense, but at the time of writing there is limited robust trial evidence that tapering prevents long-term regain compared with stopping directly. If your prescriber suggests tapering, they will set out the plan. Don't reduce your dose on your own without guidance.

Maintenance options

Some people and prescribers explore longer-term maintenance strategies, such as:

• Continuing at the lowest effective dose that maintains weight
• Switching to a GLP-1 tablet. In the ATTAIN-MAINTAIN trial, people who switched from injectable tirzepatide or semaglutide to orforglipron (Foundayo) kept, on average, around three-quarters of their earlier weight loss over a year, compared with about 38% to 49% on placebo. Orforglipron was authorised in the UK by the MHRA in August 2026. See our guide to switching from an injection to a tablet.
• Longer intervals between doses. This is not a licensed way of using these medicines and should only be considered by a prescriber.

These options are prescriber decisions. Our guides to Mounjaro maintenance and Wegovy maintenance and stopping go into more detail.

Habits that support maintenance

No lifestyle strategy fully replaces the effect of medicine for most people, but certain habits are associated with better maintenance after weight loss. Building them while you're still on treatment gives them time to become routine.

Nutrition

• Prioritise protein at each meal to support fullness and muscle. See our guide to protein on GLP-1 medication.
• Plenty of fibre from vegetables, fruit, pulses and wholegrains helps fullness. UK guidance recommends 30 g of fibre a day for adults.
• Regular meals rather than long gaps followed by large meals.
• Limit liquid calories and alcohol.
• Notice portion drift as appetite returns.

Our guide to what to eat on GLP-1 medication covers these points.

Physical activity

Physical activity is one of the most consistent features of people who maintain weight loss. UK guidelines recommend at least 150 minutes of moderate activity a week, plus strength exercises on at least two days. Resistance exercise is particularly important to preserve muscle, which supports metabolism and physical function. See our guides on preserving muscle and exercise on GLP-1 medication.

Monitoring

Regular weighing (for example, weekly) helps you spot regain early. Agree with your prescriber in advance on a threshold that would prompt a review. Measuring your waist can also be useful. See our guide on measuring progress beyond the scales.

Sleep, stress and support

Poor sleep and stress increase appetite. Social support, whether from family, friends, a group or a professional, can help maintain changes. If you notice emotional or binge eating returning, it is worth seeking specific help.

Restarting after a break

If you regain weight after stopping, restarting treatment may be an option. Points to be aware of:

• You will usually need a new consultation and assessment.
• After a break, prescribers generally restart at a lower dose and increase gradually to limit side effects.
• Eligibility may be reassessed, and the criteria for private and NHS treatment differ.
• Evidence on outcomes after restarting is still limited.

Don't restart using leftover pens or a previous dose without speaking to a prescriber. Restarting at a high dose after a break increases the risk of severe nausea, vomiting and dehydration.

Keeping perspective

It can be disheartening to hear that weight often returns after stopping. Some points to keep in mind:

• Many effective treatments for long-term conditions work only while they are taken; this is not unique to weight-loss medicines.
• Even partial maintenance can leave you lighter, and possibly healthier, than before treatment.
• Each person's experience is different.
• Your options include continuing, adjusting, switching and stopping, all of which can be discussed with a prescriber.

For more context on what to expect, see our guides to realistic weight loss expectations and the wider long-term topic hub. You can compare providers' follow-up and support on our providers page.

What stopping often feels like

Knowing what to expect can make the experience less unsettling. People commonly describe:

• Returning hunger. Usually noticeable within a few weeks of the last weekly injection, as the medicine is cleared from the body. Daily tablets wear off more quickly after the last dose.
• More "food noise". Thoughts about food may become more frequent and intrusive.
• Larger portions feeling comfortable again. The sense of fullness after small meals tends to fade.
• Cravings returning, particularly for foods that had become less appealing on treatment.
• Fewer side effects. Nausea, constipation and reflux often settle once the medicine is stopped.

None of this means you've done anything wrong. These changes reflect the medicine leaving your body and your natural appetite signals returning.

Myths about stopping GLP-1 medicines

"Once you've lost the weight, your body will stay there"

The evidence from STEP 1 extension, STEP 4 and SURMOUNT-4 suggests the opposite for most people: without ongoing treatment, the body tends to move back towards its previous weight.

"Regain only happens to people who go back to old habits"

Habits play a part, but the trials showing regain included people who had received lifestyle support. Regain largely reflects biology: the appetite and energy changes that defend a higher weight.

"You'll end up heavier than when you started"

In the trials, people who stopped treatment were, on average, still lighter a year later than when they started, although they had regained much of what they'd lost. Individual results vary, and longer-term data are limited.

"Tapering slowly prevents regain"

Tapering may make stopping feel more manageable for some people, but at the time of writing there is limited good evidence that it prevents long-term regain.

Stopping for pregnancy

Pregnancy is one situation where stopping is essential. GLP-1 medicines should not be used during pregnancy, and the SmPCs advise stopping them before a planned pregnancy, with specific washout periods for each product. If you become pregnant unexpectedly while taking one, stop and contact your GP or prescriber promptly.

Weight changes after stopping for pregnancy are expected, and your midwife and GP can advise on healthy weight during pregnancy. If you take Mounjaro, note that tirzepatide can reduce the effectiveness of oral contraceptives, particularly around the start of treatment and dose increases, so contraception advice is important while on treatment. See our guides to GLP-1 medicines, pregnancy and fertility and GLP-1 medicines and contraception.

Stopping because of side effects

If you're stopping because of side effects, it is worth discussing alternatives first. Options a prescriber may consider include a lower dose, slower dose increases, practical steps to manage side effects, or a different medicine. However, some side effects mean you should stop straight away and seek medical advice, such as symptoms of pancreatitis or a severe allergic reaction.

A simple plan for after stopping

If you and your prescriber decide that stopping is right, a written plan can help. It might include:

A plan like this turns stopping into a managed transition rather than an abrupt end.

Stopping because of cost

Cost is one of the most common reasons people stop private treatment, and price changes, such as the September 2025 rise in the UK list price of Mounjaro, have made this a pressing issue for many. If cost is the main reason, it may be worth exploring with your prescriber whether there are alternatives before stopping altogether, such as a different medicine, a different dose, or comparing services.

Factors that affect the cost of continuing include the medicine, the dose, whether consultations and follow-up are included, and delivery charges. We don't quote prices in guides, but our prices page compares current options and our providers page shows what regulated services include.

If you do decide to stop for cost reasons, the same principles apply: plan with your prescriber, build supportive habits and monitor your weight. Being aware that regain is likely can help you prepare and seek support early if needed.

When to speak to a professional

Speak to your prescriber, GP or pharmacist if:

• You are thinking about stopping treatment, for any reason
• You have stopped and your weight is rising quickly
• You want to restart treatment after a break
• You are pregnant, planning a pregnancy or breastfeeding
• You notice low mood, anxiety or a difficult relationship with food after stopping
• You have a weight-related condition, such as type 2 diabetes or high blood pressure, that may need monitoring after stopping

Seek urgent medical help (NHS 111, or 999 in an emergency) if you have:

• Severe, persistent abdominal pain, sometimes spreading to your back, with or without vomiting
• Pain in the upper right abdomen with fever, or yellowing of the skin or eyes
• Repeated vomiting with signs of dehydration, especially after restarting treatment
• Very high or very low blood sugar readings if you have diabetes
• Signs of a severe allergic reaction, such as swelling of the face or throat, or difficulty breathing